Shares of SciSparc Ltd. (NASDAQ:SPRC – Get Free Report) traded down 4% during trading on Monday . The company traded as low as $4.14 and last traded at $4.56. 401,924 shares were traded during trading, a decline of 97% from the average session volume of 13,750,208 shares. The stock had previously closed at $4.75.
Analysts Set New Price Targets
A number of research firms have recently issued reports on SPRC. Wall Street Zen upgraded shares of SciSparc to a “sell” rating in a research report on Saturday, September 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a report on Saturday, September 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.
Read Our Latest Report on SPRC
SciSparc Price Performance
About SciSparc
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Featured Stories
- Five stocks we like better than SciSparc
- What is the Dogs of the Dow Strategy? Overview and Examples
- Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Exceptional Stocks to Build Long-Term Wealth
- Following Congress Stock Trades
- Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?
Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.
